Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Effects of thirty-times chewing per bite on secretion of glucagon-like peptide-1 in healthy volunteers and type 2 diabetic patients.

Sonoki K, Iwase M, Takata Y, Nakamoto T, Masaki C, Hosokawa R, Murakami S, Chiwata K, Inoue H.

Endocr J. 2013;60(3):311-9. Epub 2012 Nov 9.

2.

Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.

Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C, Luciani A, Zandomeneghi R, Gnudi A.

Horm Metab Res. 2002 Mar;34(3):150-4.

PMID:
11972305
3.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
4.

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.

5.

Improvement in chewing activity reduces energy intake in one meal and modulates plasma gut hormone concentrations in obese and lean young Chinese men.

Li J, Zhang N, Hu L, Li Z, Li R, Li C, Wang S.

Am J Clin Nutr. 2011 Sep;94(3):709-16. doi: 10.3945/ajcn.111.015164. Epub 2011 Jul 20.

6.

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

Diabetes. 2001 Apr;50(4):776-84.

7.

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.

PMID:
9730852
8.

Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues.

Kamoi K, Shinozaki Y, Furukawa K, Sasaki H.

Endocr J. 2011;58(10):905-11. Epub 2011 Aug 30.

9.

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

Cuthbertson J, Patterson S, O'Harte FP, Bell PM.

Metabolism. 2011 Jan;60(1):52-6. doi: 10.1016/j.metabol.2010.01.001. Epub 2010 Feb 11.

PMID:
20152998
10.

Effects of thorough mastication on postprandial plasma glucose concentrations in nonobese Japanese subjects.

Suzuki H, Fukushima M, Okamoto S, Takahashi O, Shimbo T, Kurose T, Yamada Y, Inagaki N, Seino Y, Fukui T.

Metabolism. 2005 Dec;54(12):1593-9.

PMID:
16311091
11.

Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.

Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt WE, Meier JJ.

Regul Pept. 2007 Oct 4;143(1-3):64-8. Epub 2007 Mar 20.

PMID:
17434608
12.

Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects.

Hlebowicz J, Hlebowicz A, Lindstedt S, Björgell O, Höglund P, Holst JJ, Darwiche G, Almér LO.

Am J Clin Nutr. 2009 Mar;89(3):815-21. doi: 10.3945/ajcn.2008.26807. Epub 2009 Jan 21.

13.

Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.

Lugari R, Dell'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, Marani B, Iotti M, Orlandini A, Gnudi A.

Horm Metab Res. 2000 Oct;32(10):424-8.

PMID:
11069208
14.
15.

Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.

Gutniak MK, Linde B, Holst JJ, Efendić S.

Diabetes Care. 1994 Sep;17(9):1039-44.

PMID:
7988303
16.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.

PMID:
8725855
17.

First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis.

Basso N, Capoccia D, Rizzello M, Abbatini F, Mariani P, Maglio C, Coccia F, Borgonuovo G, De Luca ML, Asprino R, Alessandri G, Casella G, Leonetti F.

Surg Endosc. 2011 Nov;25(11):3540-50. doi: 10.1007/s00464-011-1755-5. Epub 2011 Jun 3.

PMID:
21638183
18.

Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.

Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H.

Diabetes Care. 2004 May;27(5):1077-80.

PMID:
15111524
19.

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.

PMID:
12189441
20.

Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.

Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B.

J Intern Med. 2001 Jul;250(1):81-7.

Supplemental Content

Support Center